Showing 5251-5260 of 6036 results for "".
- HHS: COVID-19 Testing Reaching Capacity at Some Labs as States Grapple With Spikeshttps://modernod.com/news/hhs-covid-19-testing-reaching-capacity-at-some-labs-as-states-grapple-with-spikes/2477964/Some laboratories across the country are reaching or near capacity on COVID-19 testing as cases start to rise to record levels in some states, according to a FierceHealthcare
- Global COVID-19 Prevention Trial of Hydroxychloroquine to Resumehttps://modernod.com/news/global-covid-19-prevention-trial-of-hydroxychloroquine-to-resume/2477960/A global trial designed to test whether the anti-malaria drugs hydroxychloroquine and chloroquine can prevent infection with COVID-19 is to restart after being approved by British regulators, according to a Reuters report. The Medic
- Oculight Launches US Subsidiary OCU L&Chttps://modernod.com/news/oculight-launches-us-subsidiary-ocu-lc/2477956/Oculight announced the launch of OCU L&C, a fully-owned U.S. subsidiary. OCU L&C will focus on the commercialization of its products in the U.S. Oculight is an ophthalmic medical device developer based in Korea founded in 2017 by Dr.
- After Sale of Ellex Medical Lasers, Nova Eye Medical is Formedhttps://modernod.com/news/nova-eye-medical-launches-to-propel-glaucoma-innovation/2477952/Ellex Medical Lasers has completed the sale of its Ellex Lasers & Ultrasound business to Quantel Medical via Lumibird Group SA, and changed its name from Ellex Medical Lasers Limited to Nova Eye Medical Limited. In December 2019, Lumibird Group, the parent company of Quantel Medical, s
- Iveric bio Announces First Patient Dosed in Second Zimura Phase 3 Trial for Treatment of GAhttps://modernod.com/news/iveric-bio-announces-first-patient-dosed-in-second-zimura-phase-3-trial-for-treatment-of-ga/2477951/Iveric bio announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second phase 3 clinical trial for Zimura (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (
- Novartis Withdraws Marketing Application of Dry Eye Drug Xiidra in Europehttps://modernod.com/news/novartis-pulls-eu-filing-seeking-approval-of-xiidra-for-dry-eye-disease/2477942/Novartis has decided to withdraw its marketing application seeking approval of dry eye drug Xiidra (lifitegrast) in Europe. The decision comes after the European Medicines Agency (EMA) said the drug’s benefits did not outweigh its risks. Novartis pulled the application on June 18 after the
- DORC Launches New Range of EVA EquiPhaco Needles and Sleeveshttps://modernod.com/news/dorc-launches-new-range-of-eva-equiphaco-needles-and-sleeves/2477940/DORC announced the launch of a new range of EVA EquiPhaco needles and sleeves, which are designed to deliver superior ultrasound efficiency, improved anterior chamber stability, and easier sleeve positioning. T
- 2021 ASCRS Annual Meeting Pushed Back to Augusthttps://modernod.com/news/2021-ascrs-annual-meeting-pushed-back-to-august/2477939/ASCRS announced that it is pushing back its 2021 annual meeting in San Francisco from April to August. “This decision was thoroughly researched and discussed, and when weighed against the risks of possibly losing another meeting to the coronavirus, we felt we had no other alternative
- Visual Clinic’s Patient Flow Management Solution Aims to Help Eye Care Clinics Operate Post-COVID-19https://modernod.com/news/visual-clinics-patient-flow-management-solution-aims-to-help-eye-care-clinics-operate-post-covid-19/2477935/Visual Clinic is offering a solution designed to help eye care clinics achieve better patient flow. The software aims to help practices run at peak efficiency, improve the patient experience, maximize practice resources, and keep overhead costs low while optimizing revenue. Additionally
- CDC Broadens Guidance on Americans Facing Risk of Severe COVID-19https://modernod.com/news/cdc-broadens-guidance-on-americans-facing-risk-of-severe-covid-19/2477936/The Centers for Disease Control and Prevention on Thursday broadened its warning about who is at risk of developing severe disease from COVID-19 infection, suggesting even younger people who are obese or have other health conditions can become seriously ill if they contract the virus, according t